Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.

Autor: Yue G; Department of Pathology, UMass Memorial Medical Center, 3 Biotech, 1 Innovation Drive, University of Massachusetts, Worcester, MA 01605, USA., Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2008 Apr; Vol. 32 (4), pp. 553-8. Date of Electronic Publication: 2007 Sep 20.
DOI: 10.1016/j.leukres.2007.08.006
Abstrakt: Hypocellular myelodysplastic syndrome (MDS) represents only a small portion of MDS, of which, the clinical significance has not been well-defined. By using currently accepted age-adjusted criteria to define hypocellularity as <30% in patients <70 years old, and <20% in >70 years old, we identified 163 (15.5%) hypocelluar MDS from 1049 consecutive adult MDS patients over an 11-year period (1995-2006). Compared to normal/hypercellular MDS, hypocellular MDS patients were younger (p<0.01), less anemic (p=0.02), but more neutropenic (p<0.001) and thrombocytopenic (p=0.05), and had a comparable cytogenetic risk group distribution (p=0.09) and international prognostic scores (IPSS, p=0.13). With a median follow-up of 52 months, hypocellular MDS showed a favorable overall survival (56 months versus 28 months, log-rank p<0.0001) over normal/hypocellular MDS, and this survival preference was also demonstrated in all IPSS groups and cytogenetic risk groups, and was independent of all other risk factors (Cox regression test, p=0.01). In conclusion, our study demonstrated that hypocellular MDS has characteristic clinicopathologic features, and bone marrow hypocellularity in MDS is an independent factor which predicts a favorable outcome.
Databáze: MEDLINE
Externí odkaz: